The Flu Vaccine Face-Off Ends in a Draw - Takeaways - MDSpire
From the Journals
Clinical Guidelines

The Flu Vaccine Face-Off Ends in a Draw

Pragmatic cluster randomized crossover study found no statistically significant difference in laboratory-confirmed influenza during the 2023-2024 season

  • By

  • Kerri Miller

  • May 8, 2026

  • 5 min

Share

  • 1

    Study compared adjuvanted vs high-dose influenza vaccines.

  • 2

    Involved 429,595 patients aged 65+.

  • 3

    Found similar effectiveness rates for both vaccines.

  • 4

    Primary outcome was confirmed influenza via PCR.

  • 5

    Secondary outcomes included hospitalizations.

  • 6

    Funded by CSL Seqirus, manufacturer of adjuvanted flu vaccine.

  • 7

    Results may not generalize outside the study's population.

  • 8

    Continued recommendation for both vaccine types for older adults.

Original Source(s)

The Flu Vaccine Face-Off Ends in a Draw

  • by Kerri Miller

  • May 8, 2026

Related Content

Raman Spectroscopy Moves to the Front Line of Pandemic Preparedness

Comprehensive review highlights label-free viral detection – and the hurdles to real-world deployment

  • May 7, 2026

  • 2 min
Measuring Aerosol Chemistry in Minutes 

Nanoelectromechanical FTIR analyzes nanogram-scale aerosol samples, reducing collection times from week-long campaigns to minutes

  • May 7, 2026

  • 2 min
Rapid AST Speeds Care, Not Outcomes

Faster antibiotic optimization may still support use of rapid testing, particularly when paired with stewardship.